QUARTERLY REPORT

Q1 2023 — Quarterly report

Q1 2023PDF · 27 pages164 KB
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q
 	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED March 31, 2023
or
 	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM 	TO
Commission File Number: 1-10864
UnitedHealth Group Incorporated
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of
incorporation or organization)
41-1321939
(I.R.S. Employer
Identification No.)
UnitedHealth Group Center
9900 Bren Road East
Minnetonka, Minnesota
(Address of principal executive offices)
55343
(Zip Code)
(952) 936-1300
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class 	Trading Symbol(s) 	Name of each exchange on which registered
Common Stock, $.01 par value 	UNH 	New York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. 	Yes  	No 
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to
Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was
required to submit such files). 	Yes  	No 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,”
and “emerging growth company” in Rule 12b-2 of the Exchange Act
Large accelerated filer 	 	Accelerated filer  	Non-accelerated filer 	
Smaller reporting company  	Emerging growth company 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). 	Yes  	No 
As of April 28, 2023, there were 931,032,030 shares of the registrant’s Common Stock, $.01 par value per share, issued and outstanding.

-- 1 of 27 --

UNITEDHEALTH GROUP
Table of Contents
Page
Part I. Financial Information
Item 1. 	Financial Statements (unaudited)............................................................................................................... 	1
Condensed Consolidated Balance Sheets as of March 31, 2023 and December 31, 2022 ............................................ 	1
Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2023 and 2022..................... 	2
Condensed Consolidated Statements of Comprehensive Income for the Three Months Ended March 31, 2023 and 2022 ..... 	3
Condensed Consolidated Statements of Changes in Equity for the Three Months Ended March 31, 2023 and 2022 ........... 	4
Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2023 and 2022 .................... 	5
Notes to the Condensed Consolidated Financial Statements............................................................................... 	6
1. 	Basis of Presentation ....................................................................................................................... 	6
2. 	Investments .................................................................................................................................. 	7
3. 	Fair Value .................................................................................................................................... 	9
4. 	Medical Costs Payable ..................................................................................................................... 	10
5. 	Short-Term Borrowings and Long-Term Debt......................................................................................... 	10
6. 	Commitments and Contingencies ........................................................................................................ 	11
7. 	Business Combinations .................................................................................................................... 	12
8. 	Segment Financial Information........................................................................................................... 	13
Item 2. 	Management’s Discussion and Analysis of Financial Condition and Results of Operations ......................................... 	14
Item 3. 	Quantitative and Qualitative Disclosures About Market Risk ............................................................................. 	22
Item 4. 	Controls and Procedures ......................................................................................................................... 	22
Part II. Other Information
Item 1. 	Legal Proceedings ................................................................................................................................ 	23
Item 1A. 	Risk Factors........................................................................................................................................ 	23
Item 2. 	Unregistered Sales of Equity Securities and Use of Proceeds ............................................................................. 	23
Item 6. 	Exhibits ............................................................................................................................................. 	24
Signatures ......................................................................................................................................................... 	25

-- 2 of 27 --

PART I
ITEM 1. FINANCIAL STATEMENTS
UnitedHealth Group
Condensed Consolidated Balance Sheets
(Unaudited)
(in millions, except per share data)
March 31,
2023
December 31,
2022
Assets
Current assets:
Cash and cash equivalents..................................................................................................... 	$ 	41,913 	$ 	23,365
Short-term investments ........................................................................................................ 	4,584 	4,546
Accounts receivable, net....................................................................................................... 	22,414 	17,681
Other current receivables, net................................................................................................. 	14,696 	12,769
Assets under management..................................................................................................... 	3,837 	4,087
Prepaid expenses and other current assets .................................................................................. 	6,451 	6,621
Total current assets ................................................................................................................... 	93,895 	69,069
Long-term investments............................................................................................................... 	46,884 	43,728
Property, equipment and capitalized software, net .............................................................................. 	10,637 	10,128
Goodwill ............................................................................................................................... 	100,406 	93,352
Other intangible assets, net.......................................................................................................... 	16,165 	14,401
Other assets ............................................................................................................................ 	15,692 	15,027
Total assets............................................................................................................................ 	$ 	283,679 	$ 	245,705
Liabilities, redeemable noncontrolling interests and equity
Current liabilities:
Medical costs payable.......................................................................................................... 	$ 	31,809 	$ 	29,056
Accounts payable and accrued liabilities ................................................................................... 	29,856 	27,715
Short-term borrowings and current maturities of long-term debt ....................................................... 	9,931 	3,110
Unearned revenues ............................................................................................................. 	14,487 	3,075
Other current liabilities ........................................................................................................ 	30,399 	26,281
Total current liabilities............................................................................................................... 	116,482 	89,237
Long-term debt, less current maturities ........................................................................................... 	60,657 	54,513
Deferred income taxes ............................................................................................................... 	2,834 	2,769
Other liabilities........................................................................................................................ 	13,084 	12,839
Total liabilities ........................................................................................................................ 	193,057 	159,358
Commitments and contingencies (Note 6)
Redeemable noncontrolling interests .............................................................................................. 	4,801 	4,897
Equity:
Preferred stock, $0.001 par value — 10 shares authorized; no shares issued or outstanding ...................... 	— 	—
Common stock, $0.01 par value — 3,000 shares authorized; 932 and 934 issued and outstanding .............. 	9 	9
Retained earnings ............................................................................................................... 	88,852 	86,156
Accumulated other comprehensive loss..................................................................................... 	(7,549) 	(8,393)
Nonredeemable noncontrolling interests .................................................................................... 	4,509 	3,678
Total equity ............................................................................................................................ 	85,821 	81,450
Total liabilities, redeemable noncontrolling interests and equity ........................................................ 	$ 	283,679 	$ 	245,705
See Notes to the Condensed Consolidated Financial Statements
1

-- 3 of 27 --

UnitedHealth Group
Condensed Consolidated Statements of Operations
(Unaudited)
(in millions, except per share data) 	2023 	2022
Three Months Ended
March 31,
Revenues:
Premiums ............................................................................................................................ 	$ 	72,786 	$ 	64,070
Products.............................................................................................................................. 	10,267 	9,340
Services .............................................................................................................................. 	8,080 	6,372
Investment and other income..................................................................................................... 	798 	367
Total revenues ............................................................................................................................ 	91,931 	80,149
Operating costs:
Medical costs ....................................................................................................................... 	59,845 	52,523
Operating costs ..................................................................................................................... 	13,625 	11,401
Cost of products sold .............................................................................................................. 	9,405 	8,487
Depreciation and amortization ................................................................................................... 	970 	788
Total operating costs..................................................................................................................... 	83,845 	73,199
Earnings from operations ............................................................................................................. 	8,086 	6,950
Interest expense........................................................................................................................... 	(754) 	(433)
Earnings before income taxes ........................................................................................................ 	7,332 	6,517
Provision for income taxes ............................................................................................................. 	(1,558) 	(1,369)
Net earnings .............................................................................................................................. 	5,774 	5,148
Earnings attributable to noncontrolling interests .................................................................................... 	(163) 	(121)
Net earnings attributable to UnitedHealth Group common shareholders ................................................. 	$ 	5,611 	$ 	5,027
Earnings per share attributable to UnitedHealth Group common shareholders:
Basic.................................................................................................................................. 	$ 	6.01 	$ 	5.34
Diluted ............................................................................................................................... 	$ 	5.95 	$ 	5.27
Basic weighted-average number of common shares outstanding ............................................................ 	933 	941
Dilutive effect of common share equivalents ..................................................................................... 	10 	13
Diluted weighted-average number of common shares outstanding ......................................................... 	943 	954
Anti-dilutive shares excluded from the calculation of dilutive effect of common share equivalents....................... 	5 	2
See Notes to the Condensed Consolidated Financial Statements
2

-- 4 of 27 --

UnitedHealth Group
Condensed Consolidated Statements of Comprehensive Income
(Unaudited)
(in millions) 	2023 	2022
Three Months Ended
March 31,
Net earnings ................................................................................................................................. 	$ 	5,774 	$ 	5,148
Other comprehensive income (loss):
Gross unrealized gains (losses) on investment securities during the period ........................................... 	640 	(2,023)
Income tax effect................................................................................................................ 	(147) 	465
Total unrealized gains (losses), net of tax............................................................................. 	493 	(1,558)
Gross reclassification adjustment for net realized losses (gains) included in net earnings.......................... 	13 	(3)
Income tax effect................................................................................................................ 	(3) 	1
Total reclassification adjustment, net of tax .......................................................................... 	10 	(2)
Total foreign currency translation gains..................................................................................... 	341 	918
Other comprehensive income (loss)................................................................................................ 	844 	(642)
Comprehensive income .................................................................................................................... 	6,618 	4,506
Comprehensive income attributable to noncontrolling interests ..................................................................... 	(163) 	(121)
Comprehensive income attributable to UnitedHealth Group common shareholders ...................................... 	$ 	6,455 	$ 	4,385
See Notes to the Condensed Consolidated Financial Statements
3

-- 5 of 27 --

UnitedHealth Group
Condensed Consolidated Statements of Changes in Equity
(Unaudited)
Three months ended March 31,
(in millions) 	Shares Amount
Additional
Paid-In
Capital Retained
Earnings
Net Unrealized
(Losses) Gains
on Investments
Foreign
Currency
Translation
(Losses) Gains
Nonredeemable
Noncontrolling
Interests Total
Equity
Common Stock
Accumulated Other
Comprehensive
(Loss) Income
Balance at January 1, 2023 ................. 	934 $ 	9 $ 	— $ 	86,156 $ 	(2,778) $ 	(5,615) $ 	3,678 $ 81,450
Net earnings .................................. 	5,611 	113 	5,724
Other comprehensive income .............. 	503 	341 	844
Issuances of common stock, and related
tax effects .................................. 	2 	— 	350 	350
Share-based compensation ................. 	366 	366
Common share repurchases ................ 	(4) 	— 	(633) 	(1,378) 	(2,011)
Cash dividends paid on common shares
($1.65 per share) .......................... 	(1,537) 	(1,537)
Redeemable noncontrolling interests fair
value and other adjustments............. 	(83) 	(83)
Acquisition and other adjustments of
nonredeemable noncontrolling
interests ..................................... 	819 	819
Distribution to nonredeemable
noncontrolling interests .................. 	(101) 	(101)
Balance at March 31, 2023 ................. 	932 $ 	9 $ 	— $ 	88,852 $ 	(2,275) $ 	(5,274) $ 	4,509 $ 85,821
Balance at January 1, 2022 ................. 	941 $ 	10 $ 	— $ 	77,134 $ 	423 $ 	(5,807) $ 	3,285 $ 75,045
Net earnings .................................. 	5,027 	88 	5,115
Other comprehensive (loss) income ...... 	(1,560) 	918 	(642)
Issuances of common stock, and related
tax effects .................................. 	3 	— 	333 	333
Share-based compensation ................. 	282 	282
Common share repurchases ................ 	(5) 	— 	(484) 	(2,016) 	(2,500)
Cash dividends paid on common shares
($1.45 per share) .......................... 	(1,363) 	(1,363)
Redeemable noncontrolling interests fair
value and other adjustments............. 	(131) 	(131)
Acquisition and other adjustments of
nonredeemable noncontrolling
interests ..................................... 	91 	91
Distribution to nonredeemable
noncontrolling interests .................. 	(102) 	(102)
Balance at March 31, 2022 ................. 	939 $ 	10 $ 	— $ 	78,782 $ 	(1,137) $ 	(4,889) $ 	3,362 $ 76,128
See Notes to the Condensed Consolidated Financial Statements
4

-- 6 of 27 --

UnitedHealth Group
Condensed Consolidated Statements of Cash Flows
(Unaudited)
(in millions) 	2023 	2022
Three Months Ended
March 31,
Operating activities
Net earnings .................................................................................................................................. 	$ 	5,774 	$ 	5,148
Noncash items:
Depreciation and amortization ...................................................................................................... 	970 	788
Deferred income taxes................................................................................................................ 	(332) 	161
Share-based compensation........................................................................................................... 	362 	299
Other, net ............................................................................................................................... 	69 	17
Net change in other operating items, net of effects from acquisitions and changes in AARP balances:
Accounts receivable .................................................................................................................. 	(4,306) 	(4,521)
Other assets ............................................................................................................................ 	(1,875) 	(1,089)
Medical costs payable ................................................................................................................ 	2,467 	3,849
Accounts payable and other liabilities ............................................................................................. 	1,796 	589
Unearned revenues .................................................................................................................... 	11,402 	78
Cash flows from operating activities..................................................................................................... 	16,327 	5,319
Investing activities
Purchases of investments................................................................................................................... 	(4,894) 	(4,982)
Sales of investments ........................................................................................................................ 	456 	1,591
Maturities of investments .................................................................................................................. 	2,119 	1,759
Cash paid for acquisitions, net of cash assumed ....................................................................................... 	(7,826) 	(1,231)
Purchases of property, equipment and capitalized software.......................................................................... 	(760) 	(555)
Other, net ..................................................................................................................................... 	(115) 	(255)
Cash flows used for investing activities ................................................................................................. 	(11,020) 	(3,673)
Financing activities
Common share repurchases................................................................................................................ 	(2,000) 	(2,500)
Cash dividends paid......................................................................................................................... 	(1,537) 	(1,363)
Proceeds from common stock issuances................................................................................................. 	344 	551
Repayments of long-term debt ............................................................................................................ 	(1,375) 	(1,100)
Proceeds from short-term borrowings, net .............................................................................................. 	7,349 	3,148
Proceeds from issuance of long-term debt .............................................................................................. 	6,401 	—
Customer funds administered ............................................................................................................. 	5,012 	5,120
Other, net ..................................................................................................................................... 	(1,004) 	(1,552)
Cash flows from financing activities..................................................................................................... 	13,190 	2,304
Effect of exchange rate changes on cash and cash equivalents ...................................................................... 	51 	157
Increase in cash and cash equivalents................................................................................................. 	18,548 	4,107
Cash and cash equivalents, beginning of period .................................................................................... 	23,365 	21,375
Cash and cash equivalents, end of period ............................................................................................ 	$ 41,913 	$ 25,482
See Notes to the Condensed Consolidated Financial Statements
5

-- 7 of 27 --

UnitedHealth Group
Notes to the Condensed Consolidated Financial Statements
(Unaudited)
1. 	Basis of Presentation
UnitedHealth Group Incorporated (individually and together with its subsidiaries, “UnitedHealth Group” and the “Company”) is
a health care and well-being company with a mission to help people live healthier lives and help make the health system work
better for everyone. Our two distinct, yet complementary business platforms—Optum and UnitedHealthcare—are working to
help build a modern, high-performing health system through improved access, affordability, outcomes and experiences for the
individuals and organizations the Company is privileged to serve.
The Company has prepared the Condensed Consolidated Financial Statements according to U.S. Generally Accepted
Accounting Principles (GAAP) and has included the accounts of UnitedHealth Group and its subsidiaries. The year-end
condensed consolidated balance sheet was derived from audited financial statements, but does not include all disclosures
required by GAAP. In accordance with the rules and regulations of the U.S. Securities and Exchange Commission (SEC), the
Company has omitted certain footnote disclosures that would substantially duplicate the disclosures contained in its annual
audited Consolidated Financial Statements. Therefore, these Condensed Consolidated Financial Statements should be read
together with the Consolidated Financial Statements and the Notes included in Part II, Item 8, “Financial Statements and
Supplementary Data” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 as filed with the
SEC (2022 10-K). The accompanying Condensed Consolidated Financial Statements include all normal recurring adjustments
necessary to present the interim financial statements fairly.
Use of Estimates
These Condensed Consolidated Financial Statements include certain amounts based on the Company’s best estimates and
judgments. The Company’s most significant estimates relate to estimates and judgments for medical costs payable and goodwill.
Certain of these estimates require the application of complex assumptions and judgments, often because they involve matters
that are inherently uncertain and will likely change in subsequent periods. The impact of any change in estimates is included in
earnings in the period in which the estimate is adjusted.
Revenues — Products and Services
As of March 31, 2023 and December 31, 2022, accounts receivable related to products and services were $8.1 billion and
$7.1 billion, respectively. Revenue expected to be recognized in any future year related to remaining performance obligations,
excluding revenue pertaining to contracting having an original expected duration of one year or less, contracts where revenue
recognized as invoiced and contracts with variable consideration related undelivered performance obligations, was $12.3 billion,
of which approximately half is expected to be recognized in the next three years.
6

-- 8 of 27 --

2. 	Investments
A summary of debt securities by major security type is as follows:
(in millions) Amortized
Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses Fair
Value
March 31, 2023
Debt securities — available-for-sale:
U.S. government and agency obligations .................................................... 	$ 	4,760 	$ 	5 	$ 	(236) $ 	4,529
State and municipal obligations ............................................................... 	8,055 	65 	(365) 	7,755
Corporate obligations............................................................................ 	24,149 	59 	(1,525) 	22,683
U.S. agency mortgage-backed securities ..................................................... 	8,213 	35 	(708) 	7,540
Non-U.S. agency mortgage-backed securities ............................................... 	3,156 	1 	(283) 	2,874
Total debt securities — available-for-sale ......................................................... 	48,333 	165 	(3,117) 	45,381
Debt securities — held-to-maturity:
U.S. government and agency obligations .................................................... 	594 	— 	(10) 	584
State and municipal obligations ............................................................... 	28 	— 	(3) 	25
Corporate obligations............................................................................ 	60 	— 	— 	60
Total debt securities — held-to-maturity........................................................... 	682 	— 	(13) 	669
Total debt securities ................................................................................... 	$ 	49,015 	$ 	165 	$ 	(3,130) $ 	46,050
December 31, 2022
Debt securities — available-for-sale:
U.S. government and agency obligations .................................................... 	$ 	4,093 	$ 	1 	$ 	(285) $ 	3,809
State and municipal obligations ............................................................... 	7,702 	25 	(479) 	7,248
Corporate obligations............................................................................ 	23,675 	17 	(1,798) 	21,894
U.S. agency mortgage-backed securities ..................................................... 	7,379 	15 	(808) 	6,586
Non-U.S. agency mortgage-backed securities ............................................... 	3,077 	1 	(294) 	2,784
Total debt securities — available-for-sale ......................................................... 	45,926 	59 	(3,664) 	42,321
Debt securities — held-to-maturity:
U.S. government and agency obligations .................................................... 	578 	— 	(14) 	564
State and municipal obligations ............................................................... 	29 	— 	(3) 	26
Corporate obligations............................................................................ 	89 	— 	— 	89
Total debt securities — held-to-maturity........................................................... 	696 	— 	(17) 	679
Total debt securities ................................................................................... 	$ 	46,622 	$ 	59 	$ 	(3,681) $ 	43,000
The Company held $3.9 billion and $3.7 billion of equity securities as of March 31, 2023 and December 31, 2022, respectively.
The Company’s investments in equity securities primarily consist of employee savings plan related investments, venture
investments and shares of Brazilian real denominated fixed-income funds with readily determinable fair values. Additionally,
the Company’s investments included $1.5 billion of equity method investments in operating businesses in the health care sector
as of March 31, 2023 and December 31, 2022. The allowance for credit losses on held-to-maturity securities at March 31, 2023
and December 31, 2022 was not material.
7

-- 9 of 27 --

The amortized cost and fair value of debt securities as of March 31, 2023, by contractual maturity, were as follows:
(in millions) Amortized
Cost Fair
Value Amortized
Cost Fair
Value
Available-for-Sale 	Held-to-Maturity
Due in one year or less ................................................................................. 	$ 	4,722 	$ 	4,691 	$ 	377 	$ 	376
Due after one year through five years ............................................................... 	14,356 	13,708 	261 	254
Due after five years through ten years ............................................................... 	12,240 	11,217 	24 	22
Due after ten years ...................................................................................... 	5,646 	5,351 	20 	17
U.S. agency mortgage-backed securities ............................................................ 	8,213 	7,540 	— 	—
Non-U.S. agency mortgage-backed securities ...................................................... 	3,156 	2,874 	— 	—
Total debt securities .................................................................................... 	$ 	48,333 	$ 	45,381 	$ 	682 	$ 	669
The fair value of available-for-sale debt securities with gross unrealized losses by major security type and length of time that
individual securities have been in a continuous unrealized loss position were as follows:
(in millions) Fair
Value
Gross
Unrealized
Losses Fair
Value
Gross
Unrealized
Losses Fair
Value
Gross
Unrealized
Losses
Less Than 12 Months 	12 Months or Greater 	Total
March 31, 2023
Debt securities — available-for-sale:
U.S. government and agency obligations .......... 	$ 	1,279 	$ 	(12) $ 	1,825 	$ 	(224) $ 	3,104 	$ 	(236)
State and municipal obligations ..................... 	1,898 	(30) 	3,110 	(335) 	5,008 	(365)
Corporate obligations ................................. 	6,337 	(178) 	12,443 	(1,347) 	18,780 	(1,525)
U.S. agency mortgage-backed securities ........... 	1,589 	(55) 	4,274 	(653) 	5,863 	(708)
Non-U.S. agency mortgage-backed securities..... 	783 	(26) 	1,989 	(257) 	2,772 	(283)
Total debt securities — available-for-sale ............... 	$ 	11,886 	$ 	(301) $ 	23,641 	$ 	(2,816) $ 	35,527 	$ 	(3,117)
December 31, 2022
Debt securities — available-for-sale:
U.S. government and agency obligations .......... 	$ 	2,007 	$ 	(96) $ 	1,290 	$ 	(189) $ 	3,297 	$ 	(285)
State and municipal obligations ..................... 	4,630 	(288) 	1,178 	(191) 	5,808 	(479)
Corporate obligations ................................. 	13,003 	(893) 	6,637 	(905) 	19,640 	(1,798)
U.S. agency mortgage-backed securities ........... 	3,561 	(345) 	2,239 	(463) 	5,800 	(808)
Non-U.S. agency mortgage-backed securities..... 	1,698 	(128) 	976 	(166) 	2,674 	(294)
Total debt securities — available-for-sale ............... 	$ 	24,899 	$ 	(1,750) $ 	12,320 	$ 	(1,914) $ 	37,219 	$ 	(3,664)
The Company’s unrealized losses from debt securities as of March 31, 2023 were generated from approximately 32,000
positions out of a total of 42,000 positions. The Company believes that it will collect the timely principal and interest due on its
debt securities that have an amortized cost in excess of fair value. The unrealized losses were primarily caused by interest rate
increases and not by unfavorable changes in the credit quality associated with these securities which impacted the Company’s
assessment on collectability of principal and interest. At each reporting period, the Company evaluates available-for-sale debt
securities for any credit-related impairment when the fair value of the investment is less than its amortized cost. The Company
evaluated the expected cash flows, the underlying credit quality and credit ratings of the issuers noting no significant credit
deterioration since purchase. As of March 31, 2023, the Company did not have the intent to sell any of the available-for-sale
debt securities in an unrealized loss position. Therefore, the Company believes these losses to be temporary. The allowance for
credit losses on available-for-sale debt securities at March 31, 2023 and December 31, 2022 was not material.
8

-- 10 of 27 --

3. 	Fair Value
Certain assets and liabilities are measured at fair value in the Condensed Consolidated Financial Statements or have fair values
disclosed in the Notes to the Condensed Consolidated Financial Statements. These assets and liabilities are classified into one of
three levels of a hierarchy defined by GAAP.
For a description of the methods and assumptions that are used to estimate the fair value and determine the fair value hierarchy
classification of each class of financial instrument, see Note 4 of Notes to the Consolidated Financial Statements included in
Part II, Item 8, “Financial Statements and Supplementary Data” in the 2022 10-K.
The following table presents a summary of fair value measurements by level and carrying values for items measured at fair
value on a recurring basis in the Condensed Consolidated Balance Sheets:
(in millions)
Quoted Prices
in Active
Markets
(Level 1)
Other
Observable
Inputs
(Level 2)
Unobservable
Inputs
(Level 3)
Total
Fair and
Carrying
Value
March 31, 2023
Cash and cash equivalents ...................................................................... 	$ 	41,851 	$ 	62 	$ 	— 	$ 41,913
Debt securities — available-for-sale:
U.S. government and agency obligations .............................................. 	4,122 	407 	— 	4,529
State and municipal obligations ......................................................... 	— 	7,755 	— 	7,755
Corporate obligations...................................................................... 	16 	22,486 	181 	22,683
U.S. agency mortgage-backed securities ............................................... 	— 	7,540 	— 	7,540
Non-U.S. agency mortgage-backed securities......................................... 	— 	2,874 	— 	2,874
Total debt securities — available-for-sale ................................................... 	4,138 	41,062 	181 	45,381
Equity securities.................................................................................. 	2,128 	35 	70 	2,233
Assets under management ...................................................................... 	1,491 	2,245 	101 	3,837
Total assets at fair value ........................................................................ 	$ 	49,608 	$ 43,404 	$ 	352 	$ 93,364
Percentage of total assets at fair value........................................................ 	53% 	46% 	1% 	100%
December 31, 2022
Cash and cash equivalents ...................................................................... 	$ 	23,202 	$ 	163 	$ 	— 	$ 23,365
Debt securities — available-for-sale:
U.S. government and agency obligations .............................................. 	3,505 	304 	— 	3,809
State and municipal obligations ......................................................... 	— 	7,248 	— 	7,248
Corporate obligations...................................................................... 	7 	21,695 	192 	21,894
U.S. agency mortgage-backed securities ............................................... 	— 	6,586 	— 	6,586
Non-U.S. agency mortgage-backed securities......................................... 	— 	2,784 	— 	2,784
Total debt securities — available-for-sale ................................................... 	3,512 	38,617 	192 	42,321
Equity securities.................................................................................. 	2,043 	35 	70 	2,148
Assets under management ...................................................................... 	1,788 	2,203 	96 	4,087
Total assets at fair value ........................................................................ 	$ 	30,545 	$ 41,018 	$ 	358 	$ 71,921
Percentage of total assets at fair value........................................................ 	42% 	57% 	1% 	100%
There were no transfers in or out of Level 3 financial assets or liabilities during the three months ended March 31, 2023 or 2022.
9

-- 11 of 27 --

The following table presents a summary of fair value measurements by level and carrying values for certain financial
instruments not measured at fair value on a recurring basis in the Condensed Consolidated Balance Sheets:
(in millions)
Quoted Prices
in Active
Markets
(Level 1)
Other
Observable
Inputs
(Level 2)
Unobservable
Inputs
(Level 3)
Total
Fair
Value
Total
Carrying
Value
March 31, 2023
Debt securities — held-to-maturity ............................... 	$ 	595 	$ 	74 	$ 	— 	$ 	669 	$ 	682
Long-term debt and other financing obligations ................ 	$ 	— 	$ 	60,307 	$ 	— 	$ 	60,307 	$ 	62,360
December 31, 2022
Debt securities — held-to-maturity ............................... 	$ 	577 	$ 	102 	$ 	— 	$ 	679 	$ 	696
Long-term debt and other financing obligations ................ 	$ 	— 	$ 	53,626 	$ 	— 	$ 	53,626 	$ 	56,823
Nonfinancial assets and liabilities or financial assets and liabilities that are measured at fair value on a nonrecurring basis are
subject to fair value adjustments only in certain circumstances, such as when the Company records an impairment. There were
no significant fair value adjustments for these assets and liabilities recorded during the three months ended March 31, 2023 or
2022.
4. 	Medical Costs Payable
The following table shows the components of the change in medical costs payable for the three months ended March 31:
(in millions) 	2023 	2022
Medical costs payable, beginning of period ......................................................................................... 	$ 	29,056 	$ 	24,483
Acquisitions ............................................................................................................................... 	1 	8
Reported medical costs:
Current year ......................................................................................................................... 	60,315 	52,813
Prior years ........................................................................................................................... 	(470) 	(290)
Total reported medical costs............................................................................................................ 	59,845 	52,523
Medical payments:
Payments for current year......................................................................................................... 	(35,087) 	(29,589)
Payments for prior years .......................................................................................................... 	(22,006) 	(18,749)
Total medical payments ................................................................................................................. 	(57,093) 	(48,338)
Medical costs payable, end of period ................................................................................................. 	$ 	31,809 	$ 	28,676
For the three months ended March 31, 2023 and 2022, prior years’ medical cost reserve development included no individual
factors that were significant. Medical costs payable included reserves for claims incurred by insured customers but not yet reported
to the Company of $21.7 billion and $20.0 billion at March 31, 2023 and December 31, 2022, respectively.
5. 	Short-Term Borrowings and Long-Term Debt
In March 2023, the Company issued $6.5 billion of senior unsecured notes consisting of the following:
(in millions, except percentages) 	Par Value
4.250% notes due January 2029 ....................................................................................................................... 	$ 	1,250
4.500% notes due April 2033 .......................................................................................................................... 	1,500
5.050% notes due April 2053 .......................................................................................................................... 	2,000
5.200% notes due April 2063 .......................................................................................................................... 	1,750
As of March 31, 2023, the Company had $8.2 billion of commercial paper outstanding, with a weighted-average annual interest
rate of 5.2%.
10

-- 12 of 27 --

For more information on the Company’s short-term borrowings, debt covenants and long-term debt, see Note 8 of Notes to the
Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” in the 2022
10-K.
6. 	Commitments and Contingencies
Legal Matters
The Company is frequently made party to a variety of legal actions and regulatory inquiries, including class actions and suits
brought by members, care providers, consumer advocacy organizations, customers and regulators, relating to the Company’s
businesses, including management and administration of health benefit plans and other services. These matters include medical
malpractice, employment, intellectual property, antitrust, privacy and contract claims and claims related to health care benefits
coverage and other business practices.
The Company records liabilities for its estimates of probable costs resulting from these matters where appropriate. Estimates of
costs resulting from legal and regulatory matters involving the Company are inherently difficult to predict, particularly where
the matters: involve indeterminate claims for monetary damages or may involve fines, penalties or punitive damages; present
novel legal theories or represent a shift in regulatory policy; involve a large number of claimants or regulatory bodies; are in the
early stages of the proceedings; or could result in a change in business practices. Accordingly, the Company is often unable to
estimate the losses or ranges of losses for those matters where there is a reasonable possibility or it is probable a loss may be
incurred.
Government Investigations, Audits and Reviews
The Company has been involved or is currently involved in various governmental investigations, audits and reviews. These
include routine, regular and special investigations, audits and reviews by the Centers for Medicare and Medicaid Services
(CMS), state insurance and health and welfare departments, state attorneys general, the Office of the Inspector General, the
Office of Personnel Management, the Office of Civil Rights, the Government Accountability Office, the Federal Trade
Commission, U.S. Congressional committees, the U.S. Department of Justice (DOJ), the SEC, the Internal Revenue Service, the
U.S. Drug Enforcement Administration, the U.S. Department of Labor, the Federal Deposit Insurance Corporation, the
Consumer Financial Protection Bureau (CFPB), the Defense Contract Audit Agency and other governmental authorities.
Similarly, our international businesses are also subject to investigations, audits and reviews by applicable foreign governments,
including South American and other non-U.S. governmental authorities. Certain of the Company’s businesses have been
reviewed or are currently under review, including for, among other matters, compliance with coding and other requirements
under the Medicare risk-adjustment model. CMS has selected certain of the Company’s local plans for risk adjustment data
validation (RADV) audits to validate the coding practices of and supporting documentation maintained by health care providers
and such audits may result in retrospective adjustments to payments made to the Company’s health plans.
On February 14, 2017, the DOJ announced its decision to pursue certain claims within a lawsuit initially asserted against the
Company and filed under seal by a whistleblower in 2011. The whistleblower’s complaint, which was unsealed on February 15,
2017, alleges the Company made improper risk adjustment submissions and violated the False Claims Act. On February 12,
2018, the court granted in part and denied in part the Company’s motion to dismiss. In May 2018, the DOJ moved to dismiss
the Company’s counterclaims, which were filed in March 2018, and moved for partial summary judgment. In March 2019, the
court denied the government’s motion for partial summary judgment and dismissed the Company’s counterclaims without
prejudice. The Company cannot reasonably estimate the outcome which may result from this matter given its procedural status.
11

-- 13 of 27 --

7. 	Business Combinations
During the three months ended March 31, 2023, the Company completed several business combinations for total consideration
of $8.0 billion.
Acquired assets (liabilities) at acquisition date were:
(in millions)
Cash and cash equivalents ...................................................................................................................... 	$ 	142
Accounts receivable and other current assets ................................................................................................ 	530
Property, equipment and other long-term assets............................................................................................. 	659
Other intangible assets........................................................................................................................... 	2,141
Total identifiable assets acquired ........................................................................................................ 	3,472
Medical costs payable ........................................................................................................................... 	(1)
Accounts payable and other current liabilities............................................................................................... 	(467)
Other long-term liabilities....................................................................................................................... 	(698)
Total identifiable liabilities acquired .................................................................................................... 	(1,166)
Total net identifiable assets......................................................................................................... 	2,306
Goodwill ........................................................................................................................................... 	6,646
Redeemable noncontrolling interests .......................................................................................................... 	(130)
Nonredeemable noncontrolling interests...................................................................................................... 	(819)
Net assets acquired ................................................................................................................... 	$ 	8,003
The majority of goodwill is not deductible for income tax purposes. The preliminary purchase price allocations for the various
business combinations are subject to adjustment as valuation analyses, primarily related to intangible assets and contingent
liabilities, are finalized.
The acquisition date fair values and weighted-average useful lives assigned to intangible assets were:
(in millions, except years)
Fair
Value
Weighted-
Average
Useful Life
Acquired finite-lived intangible assets:
Customer-related.................................................................................................... 	$ 	234 	13 years
Trademarks and technology....................................................................................... 	220 	5 years
Other .................................................................................................................. 	10 	11 years
Total acquired finite-lived intangible assets.......................................................................... 	464 	9 years
Total acquired indefinite-lived intangible assets — operating licenses and certificates ...................... 	1,677
Total acquired intangible assets ........................................................................................ 	$ 	2,141
The results of operations and financial condition of acquired entities have been included in the Company’s consolidated results
and the results of the corresponding operating segment as of the date of acquisition. Through March 31, 2023, acquired entities
impact on revenues and net earnings was not material.
Unaudited pro forma revenues and net earnings for the three months ended March 31, 2023 and 2022, as if the business
combinations had occurred on January 1, 2022, were immaterial for both periods.
12

-- 14 of 27 --

8. 	Segment Financial Information
The Company’s four reportable segments are UnitedHealthcare, Optum Health, Optum Insight and Optum Rx. For more
information on the Company’s segments, see Part I, Item I, “Business” and Note 14 of Notes to the Consolidated Financial
Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” in the 2022 10-K. Total assets at Optum
Health increased to $80.4 billion as of March 31, 2023 compared to $69.0 billion as of December 31, 2022, primarily due to
goodwill from business combinations of $5.9 billion.
The following tables present reportable segment financial information:
(in millions) 	UnitedHealthcare Optum Health Optum Insight Optum Rx
Optum
Eliminations 	Optum
Corporate and
Eliminations Consolidated
Optum
Three Months Ended March 31, 2023
Revenues — unaffiliated customers:
Premiums .................................. $ 	67,458 	$ 	5,328 	$ 	— $ 	— $ 	— $ 5,328 $ 	— $ 	72,786
Products.................................... 	— 	44 	40 	10,183 	— 	10,267 	— 	10,267
Services .................................... 	2,555 	3,089 	1,926 	510 	— 	5,525 	— 	8,080
Total revenues — unaffiliated customers .. 	70,013 	8,461 	1,966 	10,693 	— 	21,120 	— 	91,133
Total revenues — affiliated customers ..... 	— 	14,266 	2,510 	16,679 	(859) 	32,596 	(32,596) 	—
Investment and other income................. 	455 	277 	20 	46 	— 	343 	— 	798
Total revenues .................................. $ 	70,468 	$ 	23,004 	$ 	4,496 $ 27,418 $ 	(859) $54,059 $ 	(32,596) $ 	91,931
Earnings from operations ..................... $ 	4,343 	$ 	1,776 	$ 	907 $ 	1,060 $ 	— $ 3,743 $ 	— $ 	8,086
Interest expense................................. 	— 	— 	— 	— 	— 	— 	(754) 	(754)
Earnings before income taxes ................ $ 	4,343 	$ 	1,776 	$ 	907 $ 	1,060 $ 	— $ 3,743 $ 	(754) $ 	7,332
Three Months Ended March 31, 2022
Revenues — unaffiliated customers:
Premiums .................................. $ 	59,937 	$ 	4,133 	$ 	— $ 	— $ 	— $ 4,133 $ 	— $ 	64,070
Products.................................... 	— 	6 	40 	9,294 	— 	9,340 	— 	9,340
Services .................................... 	2,515 	2,558 	974 	325 	— 	3,857 	— 	6,372
Total revenues — unaffiliated customers .. 	62,452 	6,697 	1,014 	9,619 	— 	17,330 	— 	79,782
Total revenues — affiliated customers ..... 	— 	9,829 	2,138 	14,291 	(553) 	25,705 	(25,705) 	—
Investment and other income................. 	143 	156 	67 	1 	— 	224 	— 	367
Total revenues .................................. $ 	62,595 	$ 	16,682 	$ 	3,219 $ 23,911 $ 	(553) $43,259 $ 	(25,705) $ 	80,149
Earnings from operations ..................... $ 	3,798 	$ 	1,366 	$ 	847 $ 	939 $ 	— $ 3,152 $ 	— $ 	6,950
Interest expense................................. 	— 	— 	— 	— 	— 	— 	(433) 	(433)
Earnings before income taxes ................ $ 	3,798 	$ 	1,366 	$ 	847 $ 	939 $ 	— $ 3,152 $ 	(433) $ 	6,517
13

-- 15 of 27 --

ITEM 2. 	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS
The following discussion should be read together with the accompanying Condensed Consolidated Financial Statements and
Notes and with our 2022 10-K, including the Consolidated Financial Statements and Notes included in Part II, Item 8,
“Financial Statements and Supplementary Data” in that report. Unless the context indicates otherwise, references to the terms
“UnitedHealth Group,” the “Company,” “we,” “our” or “us” used throughout this Management’s Discussion and Analysis of
Financial Condition and Results of Operations refer to UnitedHealth Group Incorporated and its consolidated subsidiaries.
Readers are cautioned that the statements, estimates, projections or outlook contained in this Management’s Discussion and
Analysis of Financial Condition and Results of Operations, including discussions regarding financial prospects, economic
conditions, trends and uncertainties contained in this Item 2, may constitute forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve risks and
uncertainties that may cause our actual results to differ materially from the results discussed or implied in the forward-looking
statements. A description of some of the risks and uncertainties is set forth in Part I, Item 1A, “Risk Factors” in our 2022 10-K
and in the discussion below.
EXECUTIVE OVERVIEW
General
UnitedHealth Group is a health care and well-being company with a mission to help people live healthier lives and help make
the health system work better for everyone. Our two distinct, yet complementary business platforms—Optum and
UnitedHealthcare—are working to help build a modern, high-performing health system through improved access, affordability,
outcomes and experiences for the individuals and organizations we are privileged to serve.
We have four reportable segments:
• 	Optum Health;
• 	Optum Insight;
• 	Optum Rx; and
• 	UnitedHealthcare, which includes UnitedHealthcare Employer & Individual, UnitedHealthcare Medicare & Retirement and
UnitedHealthcare Community & State.
Further information on our business is presented in Part I, Item 1, “Business” and Part II, Item 7, “Management’s Discussion
and Analysis of Financial Condition and Results of Operations” in our 2022 10-K and additional information on our segments
can be found in this Item 2 and in Note 8 of Notes to the Condensed Consolidated Financial Statements included in Part I,
Item 1 of this report.
Business Trends
Our businesses participate in the United States, South America and certain other international health markets. We expect overall
spending on health care to continue to grow in the future due to inflation, medical technology and pharmaceutical advancement,
regulatory requirements, demographic trends in the population and national interest in health and well-being. The rate of market
growth may be affected by a variety of factors, including macroeconomic conditions and regulatory changes, which could
impact our results of operations, including our continued efforts to control health care costs.
Pricing Trends. To price our health care benefits, products and services, we start with our view of expected future costs,
including inflation and labor market dynamics. We frequently evaluate and adjust our approach in each of the local markets we
serve, considering all relevant factors, such as product positioning, price competitiveness and environmental, competitive,
legislative and regulatory considerations, including minimum medical loss ratio thresholds and similar revenue adjustments. We
will continue seeking to balance growth and profitability across all these dimensions.
14

-- 16 of 27 --

The commercial risk market remains highly competitive in the small group, large group and individual segments. We expect
broad-based competition to continue as the industry adapts to individual and employer needs.
Government programs in the community and senior sector tend to receive lower rates of increase than the commercial market
due to governmental budget pressures and lower cost trends.
Medical Cost Trends. Our medical cost trends primarily relate to changes in unit costs, care activity and prescription drug costs.
We endeavor to mitigate those increases by engaging physicians and consumers with information and helping them make
clinically sound choices, with the objective of helping them achieve quality, affordable care.
Regulatory Trends and Uncertainties
Medicare Advantage Rates. Medicare Advantage rate notices over the years have at times resulted in industry base rates well
below industry forward medical trend. For example, the Final Notice for 2024 rates resulted in an industry base rate decrease,
well short of what is an increasing industry forward medical cost trend, creating continued pressure in the Medicare Advantage
program. Further, substantial revisions to the risk adjustment model, which serves to adjust rates to reflect a patient’s health
status and care resource needs, will result in reduced funding and potentially benefits for people, especially those with some of
the greatest health and social challenges.
As a result of ongoing Medicare funding pressures, there are adjustments we can make to partially offset these rate pressures
and reductions for a particular period. For example, we can seek to intensify our medical and operating cost management, make
changes to the size and composition of our care provider networks, adjust member benefits and implement or increase the
member premiums supplementing the monthly payments we receive from the government. Additionally, we decide annually on
a county-by-county basis where we will offer Medicare Advantage plans.
SELECTED OPERATING PERFORMANCE AND OTHER SIGNIFICANT ITEMS
The following summarizes select first quarter 2023 year-over-year operating comparisons to first quarter 2022 and other
financial results.
• 	Consolidated revenues grew 15%, UnitedHealthcare revenues grew 13% and Optum revenues grew 25%.
• 	UnitedHealthcare served 1.9 million more people, driven by growth across our U.S. businesses.
• 	Consolidated earnings from operations of $8.1 billion compared to $7.0 billion last year, included growth of 14% at
UnitedHealthcare and 19% at Optum.
• 	Diluted earnings per common share were $5.95.
• 	Cash flows from operations for the three months ended March 31, 2023 were $16.3 billion.
• 	Return on equity was 28.2%.
15

-- 17 of 27 --

RESULTS SUMMARY
The following table summarizes our consolidated results of operations and other financial information:
(in millions, except percentages and per share data) 	2023 	2022 	2023 vs. 2022
Three Months Ended
March 31,
Increase/
(Decrease)
Revenues:
Premiums .................................................................................................. 	$ 	72,786 	$ 	64,070 	$ 	8,716 	14%
Products .................................................................................................... 	10,267 	9,340 	927 	10
Services .................................................................................................... 	8,080 	6,372 	1,708 	27
Investment and other income ........................................................................... 	798 	367 	431 	117
Total revenues................................................................................................... 	91,931 	80,149 	11,782 	15
Operating costs:
Medical costs .............................................................................................. 	59,845 	52,523 	7,322 	14
Operating costs............................................................................................ 	13,625 	11,401 	2,224 	20
Cost of products sold..................................................................................... 	9,405 	8,487 	918 	11
Depreciation and amortization.......................................................................... 	970 	788 	182 	23
Total operating costs ........................................................................................... 	83,845 	73,199 	10,646 	15
Earnings from operations...................................................................................... 	8,086 	6,950 	1,136 	16
Interest expense ................................................................................................. 	(754) 	(433) 	(321) 	74
Earnings before income taxes................................................................................. 	7,332 	6,517 	815 	13
Provision for income taxes .................................................................................... 	(1,558) 	(1,369) 	(189) 	14
Net earnings ..................................................................................................... 	5,774 	5,148 	626 	12
Earnings attributable to noncontrolling interests .......................................................... 	(163) 	(121) 	(42) 	35
Net earnings attributable to UnitedHealth Group common shareholders .............................. 	$ 	5,611 	$ 	5,027 	$ 	584 	12%
Diluted earnings per share attributable to UnitedHealth Group common shareholders ............. 	$ 	5.95 	$ 	5.27 	$ 	0.68 	13%
Medical care ratio (a) .......................................................................................... 	82.2% 	82.0% 	0.2%
Operating cost ratio............................................................................................. 	14.8 	14.2 	0.6
Operating margin ............................................................................................... 	8.8 	8.7 	0.1
Tax rate........................................................................................................... 	21.2 	21.0 	0.2
Net earnings margin (b) ....................................................................................... 	6.1 	6.3 	(0.2)
Return on equity (c) ............................................................................................ 	28.2% 	27.8% 	0.4%
(a) Medical care ratio (MCR) is calculated as medical costs divided by premium revenue.
(b) Net earnings margin attributable to UnitedHealth Group shareholders.
(c) Return on equity is calculated as annualized net earnings attributable to UnitedHealth Group common shareholders divided by average shareholders’ equity.
Average shareholders’ equity is calculated using the shareholders’ equity balance at the end of the preceding year and the shareholders’ equity balances at
the end of each of the quarters in the year presented.
2023 RESULTS OF OPERATIONS COMPARED TO 2022 RESULTS OF OPERATIONS
Consolidated Financial Results
Revenues
The increases in revenues were primarily driven by growth in the number of people served through Medicare Advantage and
Medicaid, pricing trends and growth across the Optum businesses.
Medical Costs and MCR
Medical costs increased primarily due to growth in people served through Medicare Advantage and Medicaid. The MCR
increased as a result of business mix.
16

-- 18 of 27 --

Operating Cost Ratio
The operating cost ratio increased primarily due to business mix and investments to support future growth, partially offset by
continued productivity advances.
Reportable Segments
See Note 8 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this report for more
information on our segments. We utilize various metrics to evaluate and manage our reportable segments, including people
served by UnitedHealthcare by major market segment and funding arrangement, people served by Optum Health and adjusted
scripts for Optum Rx. These metrics are the main drivers of revenue, earnings and cash flows at each business. The metrics also
allow management and investors to evaluate and understand business mix, including the level and scope of services provided to
people and pricing trends when comparing the metrics to revenue by segment.
The following table presents a summary of the reportable segment financial information:
(in millions, except percentages) 	2023 	2022 	2023 vs. 2022
Three Months Ended
March 31, Increase/
(Decrease)
Revenues
UnitedHealthcare ............................................................................................... 	$ 	70,468 	$ 	62,595 	$ 	7,873 	13%
Optum Health ............................................................................................. 	23,004 	16,682 	6,322 	38
Optum Insight............................................................................................. 	4,496 	3,219 	1,277 	40
Optum Rx.................................................................................................. 	27,418 	23,911 	3,507 	15
Optum eliminations ...................................................................................... 	(859) 	(553) 	(306) 	55
Optum ............................................................................................................ 	54,059 	43,259 	10,800 	25
Eliminations ..................................................................................................... 	(32,596) 	(25,705) 	(6,891) 	27
Consolidated revenues ......................................................................................... 	$ 	91,931 	$ 	80,149 	$ 11,782 	15%
Earnings from operations
UnitedHealthcare ............................................................................................... 	$ 	4,343 	$ 	3,798 	$ 	545 	14%
Optum Health ............................................................................................. 	1,776 	1,366 	410 	30
Optum Insight............................................................................................. 	907 	847 	60 	7
Optum Rx.................................................................................................. 	1,060 	939 	121 	13
Optum ............................................................................................................ 	3,743 	3,152 	591 	19
Consolidated earnings from operations ..................................................................... 	$ 	8,086 	$ 	6,950 	$ 	1,136 	16%
Operating margin
UnitedHealthcare ............................................................................................... 	6.2% 	6.1% 	0.1%
Optum Health ............................................................................................. 	7.7 	8.2 	(0.5)
Optum Insight............................................................................................. 	20.2 	26.3 	(6.1)
Optum Rx.................................................................................................. 	3.9 	3.9 	—
Optum ............................................................................................................ 	6.9 	7.3 	(0.4)
Consolidated operating margin............................................................................... 	8.8% 	8.7% 	0.1%
17

-- 19 of 27 --

UnitedHealthcare
The following table summarizes UnitedHealthcare revenues by business:
(in millions, except percentages) 	2023 	2022 	2023 vs. 2022
Three Months Ended
March 31,
Increase/
(Decrease)
UnitedHealthcare Employer & Individual — Domestic .............................................. 	$ 	16,544 	$ 	15,822 	$722 	5%
UnitedHealthcare Employer & Individual — Global.................................................. 	2,163 	2,133 	30 	1
UnitedHealthcare Employer & Individual — Total ............................................. 	18,707 	17,955 	752 	4
UnitedHealthcare Medicare & Retirement .............................................................. 	33,006 	29,100 	3,906 	13
UnitedHealthcare Community & State .................................................................. 	18,755 	15,540 	3,215 	21
Total UnitedHealthcare revenues ................................................................... 	$ 	70,468 	$ 	62,595 	$ 	7,873 	13%
The following table summarizes the number of people served by our UnitedHealthcare businesses, by major market segment and
funding arrangement:
(in thousands, except percentages) 	2023 	2022 	2023 vs. 2022
March 31,
Increase/
(Decrease)
Commercial — Domestic:
Risk-based........................................................................................................... 	8,025 	7,950 	75 	1%
Fee-based ............................................................................................................ 	19,325 	18,460 	865 	5
Total Commercial — Domestic .............................................................................. 	27,350 	26,410 	940 	4
Medicare Advantage.................................................................................................. 	7,545 	6,890 	655 	10
Medicaid................................................................................................................ 	8,380 	7,810 	570 	7
Medicare Supplement (Standardized).............................................................................. 	4,320 	4,355 	(35) 	(1)
Total Community and Senior ................................................................................. 	20,245 	19,055 	1,190 	6
Total UnitedHealthcare — Domestic Medical ............................................................. 	47,595 	45,465 	2,130 	5
Commercial — Global ............................................................................................... 	5,295 	5,500 	(205) 	(4)
Total UnitedHealthcare — Medical.......................................................................... 	52,890 	50,965 	1,925 	4%
Supplemental Data:
Medicare Part D stand-alone .................................................................................. 	3,380 	3,360 	20 	1%
UnitedHealthcare’s revenues and earnings from operations increased due to growth in the number of people served through
individual and group Medicare Advantage plans; growth in existing Medicaid markets; including a greater mix of people with
higher acuity needs; and an increase in the number of people served through risk-based and fee-based commercial offerings.
Optum
Total revenues and earnings from operations increased due to growth across the Optum businesses. The results by segment were
as follows:
Optum Health
Revenues at Optum Health increased primarily due to organic growth in patients served under value-based care arrangements
and business combinations. Earnings from operations increased due to organic growth in the number of people served under
value-based care arrangements and cost management initiatives. Optum Health served approximately 103 million people as of
March 31, 2023 compared to 100 million people as of March 31, 2022.
18

-- 20 of 27 --

Optum Insight
Revenues and earnings from operations at Optum Insight increased due growth in business services as a result of business
combinations and growth in technology services.
Optum Rx
Revenues and earnings from operations at Optum Rx increased due to higher script volumes from growth in people served and
growth in specialty pharmacy offerings. Earnings from operations also increased as a result of continued supply chain
management initiatives. Optum Rx fulfilled 378 million and 352 million adjusted scripts in the first quarters of 2023 and 2022,
respectively.
LIQUIDITY, FINANCIAL CONDITION AND CAPITAL RESOURCES
Liquidity
Summary of our Major Sources and Uses of Cash and Cash Equivalents
(in millions) 	2023 	2022 	2023 vs. 2022
Three Months Ended
March 31, Increase/
(Decrease)
Sources of cash:
Cash provided by operating activities ......................................................... 	$ 	16,327 	$ 	5,319 	$ 	11,008
Issuances of short-term borrowings and long-term debt, net of repayments ............ 	12,375 	2,048 	10,327
Proceeds from common stock issuances ...................................................... 	344 	551 	(207)
Customer funds administered ................................................................... 	5,012 	5,120 	(108)
Total sources of cash ................................................................................... 	34,058 	13,038
Uses of cash:
Common stock repurchases ..................................................................... 	(2,000) 	(2,500) 	500
Cash paid for acquisitions, net of cash assumed ............................................. 	(7,826) 	(1,231) 	(6,595)
Purchases of investments, net of sales and maturities ...................................... 	(2,319) 	(1,632) 	(687)
Purchases of property, equipment and capitalized software ............................... 	(760) 	(555) 	(205)
Cash dividends paid .............................................................................. 	(1,537) 	(1,363) 	(174)
Other ................................................................................................ 	(1,119) 	(1,807) 	688
Total uses of cash ....................................................................................... 	(15,561) 	(9,088)
Effect of exchange rate changes on cash and cash equivalents.................................. 	51 	157 	(106)
Net increase in cash and cash equivalents .......................................................... 	$ 	18,548 	$ 	4,107 	$ 	14,441
2023 Cash Flows Compared to 2022 Cash Flows
Increased cash flows provided by operating activities were primarily driven by an increase in unearned revenue due to the
March receipt of our April CMS premium payment of $11.2 billion and increased net earnings, partially offset by changes in
working capital accounts. Other significant changes in sources or uses of cash year-over-year included increased net issuances
of short-term borrowings and long-term debt, partially offset by increased cash paid for acquisitions and net purchases of
investments.
Financial Condition
As of March 31, 2023, our cash, cash equivalent, available-for-sale debt securities and equity securities balances of $91.2 billion
included approximately $41.9 billion of cash and cash equivalents (of which $7.0 billion was available for general corporate use),
$45.4 billion of debt securities and $3.9 billion of investments in equity securities. Given the significant portion of our portfolio
held in cash and cash equivalents, we do not anticipate fluctuations in the aggregate fair value of our financial assets to have a
19

-- 21 of 27 --

material impact on our liquidity or capital position. Our available-for-sale debt securities portfolio had a weighted-average duration
of 4.0 years and a weighted-average credit rating of “Double A” as of March 31, 2023. When multiple credit ratings are available
for an individual security, the average of the available ratings is used to determine the weighted-average credit rating.
Capital Resources and Uses of Liquidity
In addition to cash flows from operations and cash and cash equivalent balances available for general corporate use, our capital
resources and uses of liquidity are as follows:
Cash Requirements. A summary of our cash requirements as of December 31, 2022 was disclosed in Part II, Item 7,
“Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our 2022 10-K. During the three
months ended March 31, 2023, there were no material changes to this previously disclosed information outside the ordinary
course of business. We believe our capital resources are sufficient to meet future, short-term and long-term, liquidity needs. We
continually evaluate opportunities to expand our operations, including through internal development of new products, programs
and technology applications and business combinations.
Short-Term Borrowings. Our revolving bank credit facilities provide liquidity support for our commercial paper borrowing
program, which facilitates the private placement of unsecured debt through independent broker-dealers, and are available for
general corporate purposes. For more information on our commercial paper and bank credit facilities, see Note 5 of Notes to the
Condensed Consolidated Financial Statements included in Part I, Item 1 of this report and Note 8 of Notes to the Consolidated
Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” in our 2022 10-K.
Our revolving bank credit facilities contain various covenants, including covenants requiring us to maintain a defined debt to
debt-plus-shareholders’ equity ratio of not more than 60%. As of March 31, 2023, our debt to debt-plus-shareholders’ equity
ratio, as defined and calculated under the credit facilities, was approximately 42%.
Long-Term Debt. Periodically, we access capital markets and issue long-term debt for general corporate purposes, such as, to
meet our working capital requirements, to refinance debt, to finance acquisitions or for share repurchases. For more information
on our long-term debt, see Note 5 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of
this report and Note 8 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and
Supplementary Data” in our 2022 10-K.
Credit Ratings. Our credit ratings as of March 31, 2023 were as follows:
Ratings 	Outlook 	Ratings 	Outlook 	Ratings 	Outlook 	Ratings 	Outlook
Moody’s 	S&P Global 	Fitch 	A.M. Best
Senior unsecured debt ........................................ 	A3 	Positive 	A+ 	Stable 	A 	Stable 	A 	Stable
Commercial paper ............................................. 	P-2 	n/a 	A-1 	n/a 	F1 	n/a 	AMB-1+ 	n/a
The availability of financing in the form of debt or equity is influenced by many factors, including our profitability, operating
cash flows, debt levels, credit ratings, debt covenants and other contractual restrictions, regulatory requirements and economic
and market conditions. A significant downgrade in our credit ratings or adverse conditions in the capital markets may increase
the cost of borrowing for us or limit our access to capital.
Share Repurchase Program. During the three months ended March 31, 2023, we repurchased approximately 4 million shares at
an average price of $484.83 per share. As of March 31, 2023, we had Board of Directors’ authorization to purchase up to
27 million shares of our common stock.
Dividends. Our quarterly cash dividend to shareholders reflects an annual dividend rate of $6.60 per share.
20

-- 22 of 27 --

For additional liquidity discussion, see Note 10 of Notes to the Consolidated Financial Statements included in Part II, Item 8,
“Financial Statements and Supplementary Data” and “Management’s Discussion and Analysis of Financial Condition and
Results of Operations” included in Part II, Item 7 in our 2022 10-K.
RECENTLY ISSUED ACCOUNTING STANDARDS
There are no recently issued accounting standards that are expected to have a material impact on our Condensed Consolidated
Financial Statements.
CRITICAL ACCOUNTING ESTIMATES
In preparing our Condensed Consolidated Financial Statements, we are required to make judgments, assumptions and estimates,
which we believe are reasonable and prudent based on the available facts and circumstances. These judgments, assumptions and
estimates affect certain of our revenues and expenses and their related balance sheet accounts and disclosure of our contingent
liabilities. We base our assumptions and estimates primarily on historical experience and consider known and projected trends.
On an ongoing basis, we re-evaluate our selection of assumptions and the method of calculating our estimates. Actual results,
however, may materially differ from our calculated estimates, and this difference would be reported in our current operations.
Our critical accounting estimates include medical costs payable and goodwill. For a detailed description of our critical accounting
estimates, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in Part II,
Item 7 in our 2022 10-K. For a detailed discussion of our significant accounting policies, see Note 2 of Notes to the Consolidated
Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” in our 2022 10-K.
FORWARD-LOOKING STATEMENTS
The statements, estimates, projections, guidance or outlook contained in this document include “forward-looking” statements
which are intended to take advantage of the “safe harbor” provisions of the federal securities law. The words “believe,”
“expect,” “intend,” “estimate,” “anticipate,” “forecast,” “outlook,” “plan,” “project,” “should” and similar expressions identify
forward-looking statements. These statements may contain information about financial prospects, economic conditions and
trends and involve risks and uncertainties. Actual results could differ materially from those that management expects, depending
on the outcome of certain factors including: our ability to effectively estimate, price for and manage medical costs; new or
changes in existing health care laws or regulations, or their enforcement or application; reductions in revenue or delays to cash
flows received under government programs; changes in Medicare, the CMS star ratings program or the application of risk
adjustment data validation audits; the DOJ’s legal action relating to the risk adjustment submission matter; our ability to
maintain and achieve improvement in quality scores impacting revenue; failure to maintain effective and efficient information
systems or if our technology products do not operate as intended; cyberattacks, other privacy/data security incidents, or our
failure to comply with related regulations; risks and uncertainties associated with our businesses providing pharmacy care
services; competitive pressures, including our ability to maintain or increase our market share; changes in or challenges to our
public sector contract awards; failure to achieve targeted operating cost productivity improvements; failure to develop and
maintain satisfactory relationships with health care payers, physicians, hospitals and other service providers; the impact of
potential changes in tax laws and regulations (including any increase in the U.S. income tax rate applicable to corporations);
increases in costs and other liabilities associated with litigation, government investigations, audits or reviews; failure to manage
successfully our strategic alliances or complete, manage or integrate strategic transactions; risks associated with public health
crises arising from large-scale medical emergencies, pandemics, natural disasters and other extreme events; fluctuations in
foreign currency exchange rates; failure to attract, develop, retain, and manage the succession of key employees and executives;
our investment portfolio performance; impairment of our goodwill and intangible assets; failure to protect proprietary rights to
our databases, software and related products; downgrades in our credit ratings; and our ability to obtain sufficient funds from
our regulated subsidiaries or from external financings to fund our obligations, maintain our debt to total capital ratio at targeted
levels, maintain our quarterly dividend payment cycle, or continue repurchasing shares of our common stock.
This above list is not exhaustive. We discuss these matters, and certain risks that may affect our business operations, financial
condition and results of operations, more fully in our filings with the SEC, including our reports on Forms 10-K, 10-Q and 8-K.
21

-- 23 of 27 --

By their nature, forward-looking statements are not guarantees of future performance or results and are subject to risks,
uncertainties and assumptions that are difficult to predict or quantify. Actual results may vary materially from expectations
expressed or implied in this document or any of our prior communications. You should not place undue reliance on forward-
looking statements, which speak only as of the date they are made. We do not undertake to update or revise any forward-
looking statements, except as required by law.
ITEM 3. 	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We manage exposure to market interest rates by diversifying investments across different fixed-income market sectors and debt
across maturities, as well as by matching a portion of our floating-rate assets and liabilities, either directly or through the use of
interest rate swap contracts. Unrealized gains and losses on investments in available-for-sale debt securities are reported in
comprehensive income.
The following table summarizes the impact of hypothetical changes in market interest rates across the entire yield curve by 1%
point or 2% points as of March 31, 2023 on our investment income and interest expense per annum, and the fair value of our
investments and debt (in millions, except percentages):
Increase (Decrease) in Market Interest Rate
Investment
Income Per
Annum
Interest
Expense Per
Annum
Fair Value of
Financial Assets
Fair Value of
Financial Liabilities
March 31, 2023
2% .................................................................................... 	$ 	1,027 	$ 	487 	$ 	(3,684) 	$ 	(8,701)
1 ...................................................................................... 	513 	244 	(1,894) 	(4,741)
(1) .................................................................................... 	(513) 	(216) 	1,979 	5,729
(2) .................................................................................... 	(1,027) 	(428) 	4,008 	12,724
Note: The impact of hypothetical changes in interest rates may not reflect the full 100 or 200 basis point change on interest income and interest expense or on
the fair value of financial assets and liabilities as the rates are assumed to not fall below zero.
ITEM 4. 	CONTROLS AND PROCEDURES
EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES
We maintain disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act
of 1934 (Exchange Act) that are designed to provide reasonable assurance that information required to be disclosed by us in
reports that we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported within the time
periods specified in SEC rules and forms; and (ii) accumulated and communicated to our management, including our principal
executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.
In connection with the filing of this quarterly report on Form 10-Q, management evaluated, under the supervision and with the
participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of the design and operation of our
disclosure controls and procedures as of March 31, 2023. Based upon that evaluation, our Chief Executive Officer and Chief
Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of
March 31, 2023.
CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING
There have been no changes in our internal control over financial reporting during the quarter ended March 31, 2023 that have
materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
22

-- 24 of 27 --

PART II. OTHER INFORMATION
ITEM 1. 	LEGAL PROCEEDINGS
A description of our legal proceedings is included in and incorporated by reference to Note 6 of Notes to the Condensed
Consolidated Financial Statements included in Part I, Item 1 of this report.
ITEM 1A. 	RISK FACTORS
In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I,
Item 1A, “Risk Factors” of our 2022 10-K, which could materially affect our business, financial condition or future results. The
risks described in our 2022 10-K are not the only risks facing us. Additional risks and uncertainties not currently known to us or
that we currently deem to be immaterial also may materially adversely affect our business, financial condition or future results.
There have been no material changes to the risk factors as disclosed in our 2022 10-K.
ITEM 2. 	UNREGISTERED SALE OF EQUITY SECURITIES AND USE OF PROCEEDS
Issuer Purchases of Equity Securities (a)
First Quarter 2023
For the Month Ended
Total Number of
Shares Purchased
Average Price Paid
Per Share
Total Number of Shares
Purchased as Part of
Publicly Announced
Plans or Programs
Maximum Number of
Shares That May Yet Be
Purchased Under The
Plans or Programs
(in millions) 	(in millions) 	(in millions)
January 31, 2023 ................................... 	1.3 	$ 	495.21 	1.3 	29.8
February 28, 2023 ................................. 	1.5 	485.22 	1.5 	28.3
March 31, 2023..................................... 	1.3 	473.89 	1.3 	27.0
Total.................................................. 	4.1 	$ 	484.83 	4.1
(a) In November 1997, our Board of Directors adopted a share repurchase program, which the Board of Directors evaluates periodically. In June 2018, the
Board of Directors renewed our share repurchase program with an authorization to repurchase up to 100 million shares of our common stock in open market
purchases or other types of transactions (including prepaid or structured repurchase programs). There is no established expiration date for the program.
23

-- 25 of 27 --

ITEM 6. 	EXHIBITS*
The following exhibits are filed or incorporated by reference herein in response to Item 601 of Regulation S-K. The Company
files Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K pursuant to the
Securities Exchange Act of 1934 under Commission File No. 1-10864.
3.1 	Certificate of Incorporation of UnitedHealth Group Incorporated (incorporated by reference to Exhibit 3.1 to the Company’s
Registration Statement on Form 8-A/A filed on July 1, 2015)
3.2 	Amended and Restated Bylaws of UnitedHealth Group Incorporated, effective February 23, 2021 (incorporated by reference to
Exhibit 3.2 to UnitedHealth Group Incorporated’s Current Report on Form 8-K filed on February 26, 2021)
4.1 	Senior Indenture, dated as of November 15, 1998, between United HealthCare Corporation and The Bank of New York
(incorporated by reference to Exhibit 4.1 to the Company’s Registration Statement on Form S-3/A, SEC File Number 333-66013,
filed on January 11, 1999)
4.2 	Amendment, dated as of November 6, 2000, to Senior Indenture, dated as of November 15, 1998, between UnitedHealth Group
Incorporated and The Bank of New York (incorporated by reference to Exhibit 4.1 to the Company’s Quarterly Report on
Form 10-Q for the quarter ended September 30, 2001)
4.3 	Instrument of Resignation, Appointment and Acceptance of Trustee, dated January 8, 2007, pursuant to the Senior Indenture,
dated as of November 15, 1998, amended November 6, 2000, among UnitedHealth Group Incorporated, The Bank of New York
and Wilmington Trust Company (incorporated by reference to Exhibit 4.3 to the Company’s Quarterly Report on Form 10-Q for
the quarter ended June 30, 2007)
4.4 	Indenture, dated as of February 4, 2008, between UnitedHealth Group Incorporated and U.S. Bank National Association
(incorporated by reference to Exhibit 4.1 to the Company’s Registration Statement on Form S-3, SEC File Number 333-149031,
filed on February 4, 2008)
31.1 	Certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1 	Certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS 	XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are
embedded within the Inline XBRL document.
101.SCH 	Inline XBRL Taxonomy Extension Schema Document.
101.CAL 	Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF 	Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB 	Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE 	Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104 	Cover Page Interactive Data File (formatted as Inline XBRL and embedded within Exhibit 101).
* 	Pursuant to Item 601(b)(4)(iii) of Regulation S-K, copies of instruments defining the rights of certain holders of long-term
debt are not filed. The Company will furnish copies thereof to the SEC upon request.
24

-- 26 of 27 --

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned thereunto duly authorized.
UNITEDHEALTH GROUP INCORPORATED
/S / ANDREW W ITTY
Andrew Witty
Chief Executive Officer
(principal executive officer)
Dated: 	May 3, 2023
/S / JOHN REX
John Rex
Executive Vice President and
Chief Financial Officer
(principal financial officer)
Dated: 	May 3, 2023
/S / T HOMAS ROOS
Thomas Roos
Senior Vice President and
Chief Accounting Officer
(principal accounting officer)
Dated: 	May 3, 2023
25

-- 27 of 27 --